Novartis.com
Annual Reporting Suite
Investors
Coronavirus
Global
Novartis site directory
Reporting Home 2020
Explore our Annual Review
Primary Menu
Annual Review
At a glance
Who we are
How we create value
2020 news highlights
Our response to COVID-19
Key performance indicators
Financial performance
Group performance
Division performance
Strategic priorities
Unleash the power of our people
Deliver transformative innovation
– Selected products in development
Embrace operational excellence
Go big on data and digital
Build trust with society
Our management
Chairman’s letter
CEO’s letter
Our corporate governance approach
Our Board of Directors
Our Executive Committee
Compensation Report summary
Photo stories
Tackling heart disease in Kenya
Using AI in the fight against COVID-19
A doctor helps her country prepare for a pandemic
Coming together to deliver for patients
Novartis in Society ESG Report
At a glance
About this report
2020 highlights
ESG management targets
Our response to COVID-19
Who we are
How we create value
Message from the Chairman
Message from the CEO
Our journey to build trust with society
Maintaining strong governance
Materiality and reporting
Engaging with stakeholders
Contributing to the Sustainable Development Goals
Valuing our impact
Strategic areas
Holding ourselves to high ethical standards
Creating a Code of Ethics
Safeguarding our company from risks
Strengthening internal assurance and advisory
Expanding the third-party risk management process
Upholding our commitment to human rights
Encouraging associates to speak up
Addressing legacy legal issues
Being part of the solution on pricing and access
Adapting medicines to address unmet needs
Developing effective affordability strategies
Integrated access programs & markets
Leaving no patient behind in sub-Saharan Africa
Patient assistance programs
Donations
Strengthening health systems
Addressing global health challenges
Joining forces to expand global access to COVID-19 solutions
Expanding the Novartis Africa Sickle Cell Disease program
Reimagining the fight against Chagas disease
Advancing a strong pipeline to help eliminate malaria
Accelerating leprosy elimination
Developing treatments for infectious and neglected tropical diseases
Taking a holistic approach to antimicrobial resistance
Being a responsible citizen
Helping ensure patient health and safety
Supporting patients and caregivers during COVID-19
Unleashing the power of our people
Enhancing environmental sustainability
Conducting animal research responsibly
Reporting and disclosures
Performance indicators 2020
Climate-related financial disclosures (TCFD)
Environmental, Social and Governance (ESG) Index
GRI content index and UNGC and SDG mapping
Sustainability Accounting Standards Board (SASB) index
Appendices
External initiatives and membership of associations
Measuring and valuing our impact
Independent Assurance Report
Annual Reporting Suite
You are here:
Reporting Home
Key figures comparison
Key figures comparison
Annual Review
Novartis in Society
back to top
